Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01117454 · ClinicalTrials.gov registry record · NA
Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia
A NA study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT01117454 is a NA study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 14 participants.
The verdict
NCT01117454, a NA study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to test whether the addition of oral flecainide to standard therapy will reduce ventricular ectopy on exercise test compared to placebo plus standard therapy in patients with Catecholaminergic Polymorphic Ventricular Tachycardia.
Interventions
- DRUG Placebo
- DRUG Beta blocker
- DRUG Flecainide Acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2011-12 |
| Est. Completion | 2015-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01117454
The ClinicalTrials.gov registry entry for NCT01117454 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01117454 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01117454 about?
NCT01117454 is a clinical study titled "Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia". The purpose of this study is to test whether the addition of oral flecainide to standard therapy will reduce ventricular ectopy on exercise test compared to placebo plus standard therapy in patients with Catecholaminergic Polymorphic Ventricular Tachycardia.
What is the current status of trial NCT01117454?
This trial is currently completed. It is a NA study. The enrollment target is 14 participants. The study started on 2011-12. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01117454?
The interventions under investigation include: Placebo (DRUG), Beta blocker (DRUG), Flecainide Acetate (DRUG).
Who is sponsoring clinical trial NCT01117454?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.